FDA To Update Quality Metrics Guidance
Executive Summary
It's the only addition to the agency's 2016 agenda.
You may also be interested in...
False Claims, Enforcement Changes Possible Under Trump Administration
Pharma lawyers suggest that much depends on who is selected for key posts – except for the Supreme Court.
Biosimilar Interchangeability May Be Losing Luster As Approval Goal
Pricing now may mean more to payers than whether the product is interchangeable.
Biosimilar Interchangeability May Be Losing Luster As Approval Goal
Pricing now may mean more to payers than whether the product is interchangeable.